Christina T. Saed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christina T. Saed has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- John Reyes Ussher
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
6 shared publications - Amanda A. Greenwell
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada; Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada; Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada
5 shared publications Farah Eaton
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
5 shared publicationsKeshav Gopal
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
5 shared publicationsRami Al Batran
Faculty of Pharmacy Université de Montréal Quebec Canada
4 shared publicationsSeyed Amirhossein Tabatabaei Dakhili
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
4 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Elsevier in Canadian Journal of Diabetes
Ovariectomy abolishes cardioprotection against diastolic dysfunction and impairs cardiac glucose oxidation in female mice with type 2 diabetes
- 20 October 2026
- Published by Elsevier in Canadian Journal of Diabetes
Open AccessOvariectomy abolishes cardioprotection against diastolic dysfunction and impairs cardiac glucose oxidation in female mice with type 2 diabetes
- Open Access
- 2 April 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (7) , e032697
Pharmacological Inhibition of Succinyl Coenzyme A:3‐Ketoacid Coenzyme A Transferase Alleviates the Progression of Diabetic Cardiomyopathy
- 2 April 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (7) , e032697
Open AccessPharmacological Inhibition of Succinyl Coenzyme A:3‐Ketoacid Coenzyme A Transferase Alleviates the Progression of Diabetic Cardiomyopathy
- 1 September 2023
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 325 (3) , C750-C757
Ketone ester administration improves glycemia in obese mice
It has been demonstrated that increased skeletal muscle ketone metabolism contributes to obesity-related hyperglycemia. Since increases in ketone supply are key determinants of organ ketone oxidation rates, we determined whether acute elevations in circulating ketones following administration of an oral ketone ester may worsen glucose homeostasis in lean or obese mice. Our work demonstrates the opposite, as acute elevations in circulating ketones improved glucose tolerance in obese mice.
- 1 September 2023
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 325 (3) , C750-C757
Ketone ester administration improves glycemia in obese mice
It has been demonstrated that increased skeletal muscle ketone metabolism contributes to obesity-related hyperglycemia. Since increases in ketone supply are key determinants of organ ketone oxidation rates, we determined whether acute elevations in circulating ketones following administration of an oral ketone ester may worsen glucose homeostasis in lean or obese mice. Our work demonstrates the opposite, as acute elevations in circulating ketones improved glucose tolerance in obese mice.
- Open Access
- 22 June 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 133 (2) , 194-201
The antianginal ranolazine fails to improve glycaemia in obese liver‐specific pyruvate dehydrogenase deficient male mice
Aims: Recent studies have demonstrated that stimulating pyruvate dehydrogenase (PDH, gene Pdha1), the rate‐limiting enzyme of glucose oxidation, can reverse obesity‐induced non‐alcoholic fatty liver disease (NAFLD), which can be achieved via treatment with the antianginal ranolazine. Accordingly, our aim was to determine whether ranolazine's ability to mitigate obesity‐induced NAFLD and hyperglycaemia requires increases in hepatic PDH activity.Methods: We generated liver‐specific PDH‐deficient (Pdha1Liver−/−) mice, which were provided a high‐fat diet for 12 weeks to induce obesity. Pdha1Liver−/− mice and their albumin‐Cre (AlbCre) littermates were randomized to treatment with either vehicle control or ranolazine (50 mg/kg) once daily via oral gavage during the final 5 weeks, following which we assessed glucose and pyruvate tolerance.Results: Pdha1Liver−/− mice exhibited no overt phenotypic differences (e.g. adiposity, glucose tolerance) when compared to their AlbCre littermates. Of interest, ranolazine treatment improved glucose tolerance and mildly reduced hepatic triacylglycerol content in obese AlbCre mice but not in obese Pdha1Liver−/− mice. The latter was independent of changes in hepatic mRNA expression of genes involved in regulating lipogenesis.Conclusions: Liver‐specific PDH deficiency is insufficient to promote an NAFLD phenotype. Nonetheless, hepatic PDH activity partially contributes to how the antianginal ranolazine improves glucose tolerance and alleviates hepatic steatosis in obesity.
- 22 June 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 133 (2) , 194-201
Open AccessThe antianginal ranolazine fails to improve glycaemia in obese liver‐specific pyruvate dehydrogenase deficient male mice
Aims: Recent studies have demonstrated that stimulating pyruvate dehydrogenase (PDH, gene Pdha1), the rate‐limiting enzyme of glucose oxidation, can reverse obesity‐induced non‐alcoholic fatty liver disease (NAFLD), which can be achieved via treatment with the antianginal ranolazine. Accordingly, our aim was to determine whether ranolazine's ability to mitigate obesity‐induced NAFLD and hyperglycaemia requires increases in hepatic PDH activity.Methods: We generated liver‐specific PDH‐deficient (Pdha1Liver−/−) mice, which were provided a high‐fat diet for 12 weeks to induce obesity. Pdha1Liver−/− mice and their albumin‐Cre (AlbCre) littermates were randomized to treatment with either vehicle control or ranolazine (50 mg/kg) once daily via oral gavage during the final 5 weeks, following which we assessed glucose and pyruvate tolerance.Results: Pdha1Liver−/− mice exhibited no overt phenotypic differences (e.g. adiposity, glucose tolerance) when compared to their AlbCre littermates. Of interest, ranolazine treatment improved glucose tolerance and mildly reduced hepatic triacylglycerol content in obese AlbCre mice but not in obese Pdha1Liver−/− mice. The latter was independent of changes in hepatic mRNA expression of genes involved in regulating lipogenesis.Conclusions: Liver‐specific PDH deficiency is insufficient to promote an NAFLD phenotype. Nonetheless, hepatic PDH activity partially contributes to how the antianginal ranolazine improves glucose tolerance and alleviates hepatic steatosis in obesity.
- 1 July 2022
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 323 (1) , E8-E20
An isoproteic cocoa butter-based ketogenic diet fails to improve glucose homeostasis and promote weight loss in obese mice
It has been demonstrated that ketogenic diets may be a nutritional strategy for alleviating hyperglycemia and promoting weight loss in obesity. However, there are a number of inconsistencies with many of these studies, especially with regard to the macronutrient and micronutrient compositions of the diets being compared. Our work demonstrates that a ketogenic diet that is both micronutrient-matched and isoproteic with its comparator diets fails to improve glycemia or promote weight loss in obese mice.
- 1 July 2022
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 323 (1) , E8-E20
An isoproteic cocoa butter-based ketogenic diet fails to improve glucose homeostasis and promote weight loss in obese mice
It has been demonstrated that ketogenic diets may be a nutritional strategy for alleviating hyperglycemia and promoting weight loss in obesity. However, there are a number of inconsistencies with many of these studies, especially with regard to the macronutrient and micronutrient compositions of the diets being compared. Our work demonstrates that a ketogenic diet that is both micronutrient-matched and isoproteic with its comparator diets fails to improve glycemia or promote weight loss in obese mice.
- 1 June 2021
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 320 (6) , H2255-H2269
Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation
Heart failure presents as the leading cause of infant mortality in individuals with Barth syndrome (BTHS), a rare genetic disorder due to mutations in the tafazzin (TAZ) gene affecting mitochondrial structure and function. Investigations into the perturbed bioenergetics in the BTHS heart remain limited. Hence, our objective was to identify the potential alterations in myocardial energy metabolism and molecular underpinnings that may contribute to the early cardiomyopathy and heart failure development in BTHS. Cardiac function and myocardial energy metabolism were assessed via ultrasound echocardiography and isolated working heart perfusions, respectively, in a mouse model of BTHS [doxycycline-inducible Taz knockdown (TazKD) mice]. In addition, we also performed mRNA/protein expression profiling for key regulators of energy metabolism in hearts from TazKD mice and their wild-type (WT) littermates. TazKD mice developed hypertrophic cardiomyopathy as evidenced by increased left ventricular anterior and posterior wall thickness, as well as increased cardiac myocyte cross-sectional area, though no functional impairments were observed. Glucose oxidation rates were markedly reduced in isolated working hearts from TazKD mice compared with their WT littermates in the presence of insulin, which was associated with decreased pyruvate dehydrogenase activity. Conversely, myocardial fatty acid oxidation rates were elevated in TazKD mice, whereas no differences in glycolytic flux or ketone body oxidation rates were observed. Our findings demonstrate that myocardial glucose oxidation is impaired before the development of overt cardiac dysfunction in TazKD mice, and may thus represent a pharmacological target for mitigating the development of cardiomyopathy in BTHS. NEW & NOTEWORTHY Barth syndrome (BTHS) is a rare genetic disorder due to mutations in tafazzin that is frequently associated with infantile-onset cardiomyopathy and subsequent heart failure. Although previous studies have provided evidence of perturbed myocardial energy metabolism in BTHS, actual measurements of flux are lacking. We now report a complete energy metabolism profile that quantifies flux in isolated working hearts from a murine model of BTHS, demonstrating that BTHS is associated with a reduction in glucose oxidation.
- 1 June 2021
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 320 (6) , H2255-H2269
Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation
Heart failure presents as the leading cause of infant mortality in individuals with Barth syndrome (BTHS), a rare genetic disorder due to mutations in the tafazzin (TAZ) gene affecting mitochondrial structure and function. Investigations into the perturbed bioenergetics in the BTHS heart remain limited. Hence, our objective was to identify the potential alterations in myocardial energy metabolism and molecular underpinnings that may contribute to the early cardiomyopathy and heart failure development in BTHS. Cardiac function and myocardial energy metabolism were assessed via ultrasound echocardiography and isolated working heart perfusions, respectively, in a mouse model of BTHS [doxycycline-inducible Taz knockdown (TazKD) mice]. In addition, we also performed mRNA/protein expression profiling for key regulators of energy metabolism in hearts from TazKD mice and their wild-type (WT) littermates. TazKD mice developed hypertrophic cardiomyopathy as evidenced by increased left ventricular anterior and posterior wall thickness, as well as increased cardiac myocyte cross-sectional area, though no functional impairments were observed. Glucose oxidation rates were markedly reduced in isolated working hearts from TazKD mice compared with their WT littermates in the presence of insulin, which was associated with decreased pyruvate dehydrogenase activity. Conversely, myocardial fatty acid oxidation rates were elevated in TazKD mice, whereas no differences in glycolytic flux or ketone body oxidation rates were observed. Our findings demonstrate that myocardial glucose oxidation is impaired before the development of overt cardiac dysfunction in TazKD mice, and may thus represent a pharmacological target for mitigating the development of cardiomyopathy in BTHS. NEW & NOTEWORTHY Barth syndrome (BTHS) is a rare genetic disorder due to mutations in tafazzin that is frequently associated with infantile-onset cardiomyopathy and subsequent heart failure. Although previous studies have provided evidence of perturbed myocardial energy metabolism in BTHS, actual measurements of flux are lacking. We now report a complete energy metabolism profile that quantifies flux in isolated working hearts from a murine model of BTHS, demonstrating that BTHS is associated with a reduction in glucose oxidation.
- Open Access
- 1 April 2021
- Published by Elsevier in Cell Reports
- Vol. 35 (1) , 108935
FoxO1 inhibition alleviates type 2 diabetes-related diastolic dysfunction by increasing myocardial pyruvate dehydrogenase activity
- 1 April 2021
- Published by Elsevier in Cell Reports
- Vol. 35 (1) , 108935
Open AccessFoxO1 inhibition alleviates type 2 diabetes-related diastolic dysfunction by increasing myocardial pyruvate dehydrogenase activity